

North Central Cancer Treatment Group

N083E: Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer

Status Change – June 19, 2009

NOTICE OF STATUS CHANGE

This study has accrued the number of patients specified in the protocol for the initial safety cohort. Thus, it will temporarily close to accrual effective immediately (Friday, June 19, 2009) for safety assessment of this cohort, per study design.

Please retain this notice with the protocol.